ArrayBridge specializes in developing and providing advanced ELISA kits for biosimilar comparison and protein analysis, catering primarily to the biomedical research sector. The company operates in the biotechnology market, focusing on clients such as pharmaceutical companies, research institutions, and clinical laboratories. ArrayBridge's business model revolves around the sale of specialized ELISA kits, which are used to compare biosimilars—biological products highly similar to already approved reference products—and to analyze protein structures and functions. These kits are essential for ensuring the efficacy and safety of biosimilars, which are critical in the development of new therapeutic drugs. ArrayBridge generates revenue through direct sales of its ELISA kits, which are priced based on their complexity and application. The company also offers additional products and services, including enzyme assays, rapid protein purification, and functional proteomics analysis. By providing these high-precision tools, ArrayBridge supports the advancement of biomedical research and the development of new treatments.

Keywords: ELISA kits, biosimilar comparison, protein analysis, biomedical research, biotechnology, pharmaceutical, clinical laboratories, enzyme assays, proteomics, therapeutic drugs.